119 related articles for article (PubMed ID: 32416694)
21. Complete sequence of neutralization protein VP2 of the recent US isolate bluetongue virus serotype 2: its relationship with VP2 species of other US serotypes.
Yamaguchi S; Fukusho A; Roy P
Virus Res; 1988 Aug; 11(1):49-58. PubMed ID: 2845683
[TBL] [Abstract][Full Text] [Related]
22. Atomic model of a nonenveloped virus reveals pH sensors for a coordinated process of cell entry.
Zhang X; Patel A; Celma CC; Yu X; Roy P; Zhou ZH
Nat Struct Mol Biol; 2016 Jan; 23(1):74-80. PubMed ID: 26641711
[TBL] [Abstract][Full Text] [Related]
23. Application of bluetongue Disabled Infectious Single Animal (DISA) vaccine for different serotypes by VP2 exchange or incorporation of chimeric VP2.
Feenstra F; Pap JS; van Rijn PA
Vaccine; 2015 Feb; 33(6):812-8. PubMed ID: 25510389
[TBL] [Abstract][Full Text] [Related]
24. Structure of Broadhaven virus by cryoelectron microscopy: correlation of structural and antigenic properties of Broadhaven virus and bluetongue virus outer capsid proteins.
Schoehn G; Moss SR; Nuttall PA; Hewat EA
Virology; 1997 Sep; 235(2):191-200. PubMed ID: 9281498
[TBL] [Abstract][Full Text] [Related]
25. VP2, VP7, and NS1 proteins of bluetongue virus targeted in avian reovirus muNS-Mi microspheres elicit a protective immune response in IFNAR(-/-) mice.
Marín-López A; Otero-Romero I; de la Poza F; Menaya-Vargas R; Calvo-Pinilla E; Benavente J; Martínez-Costas JM; Ortego J
Antiviral Res; 2014 Oct; 110():42-51. PubMed ID: 25057758
[TBL] [Abstract][Full Text] [Related]
26. Restriction analysis of conserved and variable regions of VP2 gene of Indian isolates of bluetongue virus serotype 1.
Dahiya S; Prasad G; Minakshi ; Kovi RC
Indian J Exp Biol; 2005 Mar; 43(3):272-6. PubMed ID: 15816416
[TBL] [Abstract][Full Text] [Related]
27. Identification and localization of a serotypic neutralization determinant on the VP2 protein of bluetongue virus 13.
Hwang GY; Li JK
Virology; 1993 Aug; 195(2):859-62. PubMed ID: 7687805
[TBL] [Abstract][Full Text] [Related]
28. Heterologous prime boost vaccination with DNA and recombinant modified vaccinia virus Ankara protects IFNAR(-/-) mice against lethal bluetongue infection.
Calvo-Pinilla E; Rodríguez-Calvo T; Sevilla N; Ortego J
Vaccine; 2009 Dec; 28(2):437-45. PubMed ID: 19857449
[TBL] [Abstract][Full Text] [Related]
29. Mapping the pH Sensors Critical for Host Cell Entry by a Complex Nonenveloped Virus.
Wu W; Celma CC; Kerviel A; Roy P
J Virol; 2019 Feb; 93(4):. PubMed ID: 30518645
[TBL] [Abstract][Full Text] [Related]
30. Analysis of the roles of bluetongue virus outer capsid proteins VP2 and VP5 in determination of virus serotype.
Mertens PP; Pedley S; Cowley J; Burroughs JN; Corteyn AH; Jeggo MH; Jennings DM; Gorman BM
Virology; 1989 Jun; 170(2):561-5. PubMed ID: 2543130
[TBL] [Abstract][Full Text] [Related]
31. Conserved and non-conserved regions of the outer coat protein, VP2, of the Australian bluetongue serotype 1 virus, revealed by sequence comparison to the VP2 of North American BTV serotype 10.
Gould AR
Virus Res; 1988 Feb; 9(2-3):145-58. PubMed ID: 2833046
[TBL] [Abstract][Full Text] [Related]
32. An experimental subunit vaccine based on Bluetongue virus 4 VP2 protein fused to an antigen-presenting cells single chain antibody elicits cellular and humoral immune responses in cattle, guinea pigs and IFNAR(-/-) mice.
Legisa DM; Perez Aguirreburualde MS; Gonzalez FN; Marin-Lopez A; Ruiz V; Wigdorovitz A; Martinez-Escribano JA; Ortego J; Dus Santos MJ
Vaccine; 2015 May; 33(22):2614-9. PubMed ID: 25858859
[TBL] [Abstract][Full Text] [Related]
33. DNA vaccine prime and recombinant FPV vaccine boost: an important candidate immunization strategy to control bluetongue virus type 1.
Li J; Yang T; Xu Q; Sun E; Feng Y; Lv S; Zhang Q; Wang H; Wu D
Appl Microbiol Biotechnol; 2015 Oct; 99(20):8643-52. PubMed ID: 26048472
[TBL] [Abstract][Full Text] [Related]
34. Conformation of the VP2 protein of bluetongue virus (BTV) determines the involvement in virus neutralization of highly conserved epitopes within the BTV serogroup.
White JR; Eaton BT
J Gen Virol; 1990 Jun; 71 ( Pt 6)():1325-32. PubMed ID: 1693664
[TBL] [Abstract][Full Text] [Related]
35. VP2-serotyped live-attenuated bluetongue virus without NS3/NS3a expression provides serotype-specific protection and enables DIVA.
Feenstra F; Maris-Veldhuis M; Daus FJ; Tacken MG; Moormann RJ; van Gennip RG; van Rijn PA
Vaccine; 2014 Dec; 32(52):7108-14. PubMed ID: 25454873
[TBL] [Abstract][Full Text] [Related]
36. Plant-produced Bluetongue chimaeric VLP vaccine candidates elicit serotype-specific immunity in sheep.
Mokoena NB; Moetlhoa B; Rutkowska DA; Mamputha S; Dibakwane VS; Tsekoa TL; O'Kennedy MM
Vaccine; 2019 Sep; 37(41):6068-6075. PubMed ID: 31471154
[TBL] [Abstract][Full Text] [Related]
37. Bluetongue virus without NS3/NS3a expression is not virulent and protects against virulent bluetongue virus challenge.
Feenstra F; van Gennip RGP; Maris-Veldhuis M; Verheij E; van Rijn PA
J Gen Virol; 2014 Sep; 95(Pt 9):2019-2029. PubMed ID: 24914064
[TBL] [Abstract][Full Text] [Related]
38. The Tip Region on VP2 Protein of Bluetongue Virus Contains Potential IL-4-Inducing Amino Acid Peptide Segments.
Yang JL; Chang CY; Sheng CS; Wang CC; Wang FI
Pathogens; 2020 Dec; 10(1):. PubMed ID: 33375108
[TBL] [Abstract][Full Text] [Related]
39. Immunization of knock-out α/β interferon receptor mice against lethal bluetongue infection with a BoHV-4-based vector expressing BTV-8 VP2 antigen.
Franceschi V; Capocefalo A; Calvo-Pinilla E; Redaelli M; Mucignat-Caretta C; Mertens P; Ortego J; Donofrio G
Vaccine; 2011 Apr; 29(16):3074-82. PubMed ID: 21320537
[TBL] [Abstract][Full Text] [Related]
40. A capsid protein of nonenveloped Bluetongue virus exhibits membrane fusion activity.
Forzan M; Wirblich C; Roy P
Proc Natl Acad Sci U S A; 2004 Feb; 101(7):2100-5. PubMed ID: 14762165
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
